Stock Ticker

  • Loading stock data...

AVEO Pharmaceuticals, Inc.’s (NASDAQ:AVEO) TIVO-3 Trial Results Inconclusive And Uninterpretable

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued a regulatory update after a meeting with the U.S. FDA to discuss data from the August 2019 OS analysis of the TIVO-3 study. The company also issued an update on its proposal to advance with a New Drug Application for tivozanib. The TIVO-3 study was planned to resolve the FDA’s […]

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Reports Completion Of TIVO-3 Trial Futility Analysis

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported the conclusion of a pre-planned futility assessment of the Phase III TIVO-3 study, the firm’s randomized, controlled, open-label trial to compare FOTIVDA® to sorafenib in people with refractory advanced RCC. Dependent on the data of the futility assessment, which was assessed by an independent statistician, the trial will continue as […]

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Obtains Payments From EUSA Pharma & CANbridge

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced recently the receipt of over $4 million research and development related payment from EUSA Pharma to facilitate the approval of FOTIVDA® (tivozanib), for treatment of adult patients suffering from the advanced renal cell carcinoma across the Europe. At the same time, the company received a $500,000 milestone funds from the […]

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Announces FOTIVDA® Licensed In EU For Cure Of Advanced Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced recently that the European Commission (EC) has approved FOTIVDA® (tivozanib) to be used for the treatment of adults who are diagnosed with the Advanced Renal Cell Carcinoma (RCC) within the European Union (EU), together with Norway, and Iceland regions. Tivozanib is specified for adult patients suffering from the advanced RCC […]

EU Regulators Greenlight U.S. Biotech AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s Kidney Cancer Drug

European regulators have recommended the approval of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s drug for cancer treatment. The announcement is a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market. Following the announcement on Monday, Aveo’s shares surged 58% to $1.15 in premarket trading. The European […]

Sign Up To Get Our Latest Stocks Alerts